IPO FILING: Adnexus Therapeutics, Targeting Avastin (ADNX, BMY)

By Douglas A. McIntyre Published Aug 22, 11:04AM EDT

Follow 24/7 Wall St. on Google

This post may contain links from our sponsors and affiliates, and Flywheel Publishing may receive compensation for actions taken through them.

ADNEXUS THERAPEUTICS, INC. has filed to come public via an IPO with the filed amount to sell up to $86,250,000 in common stock. Adnexus has taken the proposed ADNX ticker on NASDAQ. Lehman and UBS have been given the lead manager status, and Cowen & Co. and Lazard Capital are listed as co-managers.

This is purely a pre-development stage company in biotech. The company’s goal is to build a leading biotechnology business that discovers, develops and commercializes its novel, proprietary drug class that it call Adnectins, which are said to have competitive therapeutic, manufacturing and commercial advantages over antibodies and small molecules. It generates Adnectins from human fibronectin by using proprietary protein engineering system called PROfusion. Adnexus scientists engineer trillions of protein variations at a time in order to find the optimal Adnectin drug using this system and patent estate ‘to lead a new era in targeted biologics.’

It has a target and it has a key partner. Its first Adnectin, Angiocept, is an antagonist of the VEGFR-2 pathway and is in clinical development in the United States. Unlike Avastin, Sutent and Nexavar, the three approved agents in this market, Angiocept is designed to be both a potent and highly specific VEGFR-2 pathway antagonist. Adnexus is conducting phase 1 clinical trial of Angiocept in the United States in oncology patients and plans to move into multiple Phase II trials with the first starting in 2008. The first Adnectin-PROfusion alliance is with Bristol-Myers Squibb (NYSE:BMY) and includes up to 6 programs based on 4 targets in oncology. From this alliance, Adnexus is eligible to receive development milestones from Bristol Myers of $211.5 million for the first product directed to a certain target of the first program and $141.0 million per program for each of 5 other potential programs, plus a sales milestone of $131.0 million per program, in addition to escalating double-digit royalties on product sales.

Jon C. Ogg
August 22, 2007

About the Author Douglas A. McIntyre →

Douglas A. McIntyre is the co-founder, chief executive officer and editor in chief of 24/7 Wall St. and 24/7 Tempo. He has held these jobs since 2006.

McIntyre has written thousands of articles for 24/7 Wall St. He is an expert on corporate finance, the automotive industry, media companies and international finance. He has edited articles on national demographics, sports, personal income and travel.

His work has been quoted or mentioned in The New York Times, The Wall Street Journal, Los Angeles Times, The Washington Post, NBC News, Time, The New Yorker, HuffPost USA Today, Business Insider, Yahoo, AOL, MarketWatch, The Atlantic, Bloomberg, New York Post, Chicago Tribune, Forbes, The Guardian and many other major publications. McIntyre has been a guest on CNBC, the BBC and television and radio stations across the country.

A magna cum laude graduate of Harvard College, McIntyre also was president of The Harvard Advocate. Founded in 1866, the Advocate is the oldest college publication in the United States.

TheStreet.com, Comps.com and Edgar Online are some of the public companies for which McIntyre served on the board of directors. He was a Vicinity Corporation board member when the company was sold to Microsoft in 2002. He served on the audit committees of some of these companies.

McIntyre has been the CEO of FutureSource, a provider of trading terminals and news to commodities and futures traders. He was president of Switchboard, the online phone directory company. He served as chairman and CEO of On2 Technologies, the video compression company that provided video compression software for Adobe’s Flash. Google bought On2 in 2009.